RPAM
PCRX icon

Rhenman & Partners Asset Management’s Pacira BioSciences PCRX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-40,000
Closed -$2.12M – 99
2016
Q1 		$2.12M Buy
40,000
+5,000
+14% +$292K 0.42% 74
2015
Q4 		$2.69M Buy
+35,000
New +$1.98M 0.41% 71

Other funds holding PCRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Rhenman & Partners Asset Management's PCRX Position: Q2 2016 in Review

Rhenman & Partners Asset Management sold out of Pacira BioSciences (PCRX) in Q2 2016, closing a stake of 40,000 shares — an estimated $2.12M sold.

Rhenman & Partners Asset Management first reported a position in PCRX in Q4 2015 and held it in 2 quarters. The position peaked at $2.69M in Q4 2015. 183 funds tracked by Wall St. Rank hold PCRX as of Q2 2016.

  • Rhenman & Partners Asset Management reported no remaining Pacira BioSciences position as of Q2 2016 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 40,000 Pacira BioSciences shares in Q2 2016, an estimated $2.12M.
  • Rhenman & Partners Asset Management first reported a position in Pacira BioSciences in Q4 2015 and held it in 2 quarters.
  • Rhenman & Partners Asset Management's Pacira BioSciences position peaked at $2.69M in Q4 2015.
  • 183 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2016.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2016, filed 1 Aug 2016.